<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Exp. Biol. Med.</journal-id>
<journal-title>Experimental Biology and Medicine</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Exp. Biol. Med.</abbrev-journal-title>
<issn pub-type="epub">1535-3699</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">10559</article-id>
<article-id pub-id-type="doi">10.3389/ebm.2025.10559</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Experimental Biology and Medicine</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>A double-edged effect of hypoxia on astrocyte-derived exosome releases</article-title>
<alt-title alt-title-type="left-running-head">Tseng et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/ebm.2025.10559">10.3389/ebm.2025.10559</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Tseng</surname>
<given-names>Yang Jie</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/3032994/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Huang</surname>
<given-names>Hui-Ju</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2956294/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lin</surname>
<given-names>Chien-Hui</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Lin</surname>
<given-names>Anya Maan-Yuh</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2988431/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Ph.D. Program in Regulatory Science and Policy</institution>, <institution>National Yang-Ming Chiao-Tung University</institution>, <addr-line>Hsin-Chu</addr-line>, <country>Taiwan</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Medical Research</institution>, <institution>Taipei Veterans General Hospital</institution>, <addr-line>Taipei</addr-line>, <country>Taiwan</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Institute of Physiology</institution>, <institution>National Yang-Ming Chiao-Tung University</institution>, <addr-line>Hsin-Chu</addr-line>, <country>Taiwan</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Department of Pharmacy</institution>, <institution>National Yang-Ming Chiao-Tung University</institution>, <addr-line>Hsin-Chu</addr-line>, <country>Taiwan</country>
</aff>
<author-notes>
<corresp id="c001">&#x2a;Correspondence: Anya Maan-Yuh Lin, <email>myalin@nycu.edu.tw</email>
</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>21</day>
<month>05</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="collection">
<year>2025</year>
</pub-date>
<volume>250</volume>
<elocation-id>10559</elocation-id>
<history>
<date date-type="received">
<day>02</day>
<month>03</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>02</day>
<month>05</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2025 Tseng, Huang, Lin and Lin.</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Tseng, Huang, Lin and Lin</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Exosomes are the smallest extracellular vesicles secreted from cells, carrying different cargos, including nucleic acids, proteins and others which transfer from cells to cells. The properties of exosomes depend on the donor cells. Hypoxia, referring to a sublethal and insufficient oxygen supply, reportedly influences exosome secretion of hypoxic cells. In the present study, we focused on the effects of hypoxia on exosomes obtained from CTX-TNA2 astrocyte cells exposed to different durations of hypoxia followed by normoxia as a model of hypoxic preconditioning. To evaluate the functions of exosomes, primary cultured cortical neurons were treated with hemin, a potent neurotoxin. Our sulforhodamine B assay showed that incubation of hemin (30&#xa0;&#x3bc;M) consistently induced neuronal death. Co-incubation of exosomes from CTX-TNA2 cells subjected to 2 hr-hypoxia plus 6 hr-renormoxia (2H/6R exosomes), but not 12 hr-hypoxia plus 24 hr-renormoxia (12H/24R exosomes), attenuated hemin-induced cell death and reduction in growth associated protein 43 level (a biomarker of neurite outgrowth). Western blot assay demonstrated that 2H/6R exosomes attenuated hemin-induced elevations in inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) levels (two proinflammatory biomarkers) as well as heme oxygenase-1 (HO-1). In contrast, 12H/24R exosomes did not alter hemin-induced elevation in HO-1 but further augmented hemin-induced increases in iNOS and COX-2. Moreover, 2H/6R exosomes attenuated hemin-induced reduction in glutathione hydroperoxidase 4 (a biomarker of ferroptosis) and elevation in active caspase 3 (a biomarker of apoptosis) while 12H/24R exosomes did not effectively alter hemin-induced programed cell death. In conclusion, our study showed that 2H/6R exosomes possessed neuroprotective activities while 12H/24R exosomes had mild pro-inflammatory activities, suggesting that different hypoxic preconditionings influenced CTX-TNA2 cells which then secreted exosomes with differential biological activities. These findings highlight a double-edged role of hypoxia on exosome functions.</p>
</abstract>
<kwd-group>
<kwd>hypoxic preconditioning</kwd>
<kwd>double-edged role</kwd>
<kwd>exosomes</kwd>
<kwd>hemin</kwd>
<kwd>CTX-TNA2</kwd>
</kwd-group>
<contract-sponsor id="cn001">National Science and Technology Council<named-content content-type="fundref-id">10.13039/501100020950</named-content>
</contract-sponsor>
<contract-sponsor id="cn002">Taipei Veterans General Hospital<named-content content-type="fundref-id">10.13039/501100011912</named-content>
</contract-sponsor>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Impact statement</title>
<p>To delineate the role of hypoxic preconditioning on the exosome&#x2019;s secretion and functions, the CTX-TNA2 cells were exposed to different durations of hypoxia plus renormoxia and were found to secrete exosomes with opposite functions. One was to attenuate hemin-induced neurotoxicity and the other was to augment hemin-induced neuroinflammation. Our data suggests that in addition to exosomes secretion, hypoxic treatment plays a crucial role in modulating exosomes functions.</p>
</sec>
<sec sec-type="intro" id="s2">
<title>Introduction</title>
<p>Cells are known to secrete small membrane-bound vesicles, namely, extracellular vesicles (EVs). Extracellular vesicles differ in size, density, morphology, contents, and biomarkers [<xref ref-type="bibr" rid="B1">1</xref>&#x2013;<xref ref-type="bibr" rid="B3">3</xref>]. Exosomes are the smallest subgroup of EVs, ranging from 30 to 160&#xa0;nm. Exosomes carry various biomolecules, including proteins, lipids, and nucleic acids (RNA, DNA) which are reportedly transferred from donor cells to target cells [<xref ref-type="bibr" rid="B4">4</xref>]. Accordingly, the function of exosomes depends on the status of donor cells [<xref ref-type="bibr" rid="B2">2</xref>]. Protective exosomes from good cells are suggested to carry &#x201c;good&#x201d; cargos while detrimental exosomes from bad cells carry &#x201c;bad&#x201d; cargos [<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B5">5</xref>]. Many non-clinical and clinical studies have demonstrated cytoprotective roles of exosomes against various diseases [<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B5">5</xref>&#x2013;<xref ref-type="bibr" rid="B10">10</xref>]. For example, non-clinical studies showed that exosomes from cardiac fibroblasts inhibited heart failure and myocardial ischemic damage [<xref ref-type="bibr" rid="B7">7</xref>]. Furthermore, exosomes derived from umbilical cord mesenchymal stem cells (MSC) reportedly prevented acute liver damage in mice [<xref ref-type="bibr" rid="B8">8</xref>]. Exosomes from hypoxic MSC exert its protective action via attenuating neurological deficits, and program cell death in stroke and Alzheimer&#x2019;s models [<xref ref-type="bibr" rid="B9">9</xref>] as well as promoting bone fracture healing [<xref ref-type="bibr" rid="B10">10</xref>]. At the same time, many clinical trials focused on the protective effects of exosomes on renal diseases, type 1 diabetes, osteoarthritis, stroke, Alzheimer&#x2019;s disease, and cancers [<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B6">6</xref>].</p>
<p>Hypoxia refers to a condition in which oxygen supply is insufficient in cells, tissues, organs, and systems [<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B12">12</xref>]. A variety of protective functions via hypoxia-induced adaptation has been demonstrated. For example, a non-lethal hypoxia in the tumor microenvironment is reportedly cytoprotective to cancer cells [<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B14">14</xref>]. Furthermore, our previous studies have demonstrated that hypoxic preconditioning is neuroprotective against kainic acid-induced neurotoxicity [<xref ref-type="bibr" rid="B15">15</xref>] and ischemic stroke [<xref ref-type="bibr" rid="B16">16</xref>]. The proposed mechanisms underlying hypoxia-induced adaptation included induction of hypoxia-inducible factor-&#x3b1;, a transcription factor which is reportedly up-regulated to activate genes and is responsible for adaptation-related cellular responses [<xref ref-type="bibr" rid="B12">12</xref>]. Furthermore, hypoxia-induced adaptation may be mediated via regulation of anti-oxidative defense systems, induction of autophagy [<xref ref-type="bibr" rid="B17">17</xref>], exosome secretion [<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B10">10</xref>] and others.</p>
<p>Due to the intersection of hypoxia and exosomes, the present study focused on the effects of hypoxia on CTX-TNA2 cells-derived exosomes using hemin-induced neurotoxicity, an intracerebral hemorrhage (ICH) <italic>in vitro</italic> model [<xref ref-type="bibr" rid="B18">18</xref>]. Astrocytes are reportedly involved in homeostasis and defense of the central nervous system (CNS) [<xref ref-type="bibr" rid="B19">19</xref>]. During the insults, astrocytes are activated and may damage the nearby cells. However, recent studies proposed a neuroprotective role of astrocytes in the astrocyte polarization [<xref ref-type="bibr" rid="B20">20</xref>] following brain injury. These findings indicate that astrocytes may play beneficial or detrimental roles in CNS neurodegenerative diseases [<xref ref-type="bibr" rid="B19">19</xref>&#x2013;<xref ref-type="bibr" rid="B21">21</xref>]. Given that astrocytes are the most numerous cell type in the brain, astrocytes-derived exosomes may have a substantial influence on the progression of CNS neurodegenerative disorders, including ICH. In the present study, CTX-TNA2 astrocyte cells were exposed to different durations of hypoxia and subsequent renormoxia, including 2-h hypoxia followed by 6-h normoxia (2H/6R) and 12-h hypoxia followed by 24-h normoxia (12H/24R). Both 2H/6R exosomes and 12H/24R exosomes were collected and their functions were characterized. Our data showed that 2H/6R exosomes attenuated hemin-induced neurotoxicity while 12H/24R exosomes possessed proinflammatory activities, indicating that the role of hypoxia is double-edged in exosomes&#x2019; functions.</p>
</sec>
<sec sec-type="materials|methods" id="s3">
<title>Materials and methods</title>
<sec id="s3-1">
<title>Chemicals</title>
<p>The chemicals used were hemin (Sigma, St. Louis, MO, United States). Hemin was dissolved in ammonia water and pH value was corrected to pH 7.4. Hemin was diluted with DMEM or Neurobasal medium (NB, Thermo Fisher Scientific, Waltham, MA, United States).</p>
</sec>
<sec id="s3-2">
<title>Hypoxic preconditioning of CTX-TNA2 cells</title>
<p>CTX-TNA2, an astrocyte cell line isolated from the cortex of 1-day old rats, was purchased from Bioresource Collection and Research Center (Taiwan) and maintained in Dulbecco&#x2019;s Modified Eagle Medium (Sigma) supplemented with 10% (v/v) fetal bovine serum (Cytiva, Marlborough, MA, United States) and 1% penicillin-streptomycin-amphotericin B (Cytiva) in an incubator under 5% CO2 at 37&#xb0;C. Prior to the hypoxic preconditioning, CTX-TNA2 cells were seeded at a density of 1 &#xd7; 10<sup>6</sup> cells in a 10-cm culture dish and were incubated in 5&#xa0;mL NB without exosomes. Hypoxic treatment was conducted by incubating cells in an incubator with 1% oxygen. Two hypoxic preconditionings were designed as follows. One hypoxic treatment was to expose CTX-TNA2 cells to 2-h hypoxia followed by 6-h normoxia. The other was to expose CTX-TNA2 cells to 12-h hypoxia followed by 24-h normoxia.</p>
</sec>
<sec id="s3-3">
<title>Exosomes preparation</title>
<p>At the end of hypoxia-renormoxia treatments, exosomes obtained from the culture medium were isolated using ExoQuick (System Biosciences, Palo Alto, CA, United States). In brief, the culture medium from 10-cm culture dishes was collected and centrifuged at 2600 &#xd7; <italic>g</italic> for 30&#xa0;min at 4&#xb0;C. The supernatant was transferred to a new centrifuge tube. Five milliliters of culture medium mixed with 1&#xa0;mL of ExoQuick and the tube was placed in a refrigerator at 4&#xb0;C overnight. The supernatant was collected and centrifuged at 1,500 &#xd7; <italic>g</italic> for 30&#xa0;min at 4&#xb0;C. Again, the supernatant was collected and centrifuged at 1,500 &#xd7; <italic>g</italic> for 5&#xa0;min. After removing the remaining supernatant, the exosome pellet was re-dissolved in PBS at 4&#xb0;C and stored at 4&#xb0;C. Approximately, 5 &#xd7; 10<sup>8</sup> exosome particles obtained from 1 &#xd7; 10<sup>6</sup> cells in a 10-cm culture dish were used for further experiments as 1-fold (1x) of exosomes.</p>
</sec>
<sec id="s3-4">
<title>Nanoparticle tracking analysis and detection of zeta potentials</title>
<p>Nanoparticle Tracking Analysis (NTA) was employed to characterize exosomes, including size distribution and exosome particle concentration by NanoSight NS300 (Malvern Panalytical, Malvern, UK). This technique was capable of detecting vesicles with sizes between 0.05 and 1&#xa0;&#x3bc;m. At the same time, zeta potential of exosomes was analyzed using the Nano ZS (Malvern Panalytical).</p>
</sec>
<sec id="s3-5">
<title>Transmission electron microscopy</title>
<p>An aliquot of exosomes was applied onto an electron microscopy grid and incubated for 5&#xa0;min and fixed with 2% paraformaldehyde for 5&#xa0;min. The samples were counterstained with 1% uranyl acetate for 1&#xa0;min, air-dried overnight, and observed using a Transmission Electron Microscope JEM-1400Plus (JEOL Ltd., Tokyo, Japan).</p>
</sec>
<sec id="s3-6">
<title>RNA sequencing analysis</title>
<p>MicroRNA(miRNA) libraries were prepared using the QIAseq miRNA UDI Library Kit (Qiagen, Venlo, Netherlands) and evaluated for size distribution using the Agilent 4150 TapeStation with HS D1000 ScreenTape (Agilent, Santa Clara, CA, United States). Sequencing was conducted with single end reads (100&#xa0;bp) at a depth exceeding 10 million reads per sample. miRNA expression levels were quantified using the Qiagen GeneGlobe platform (Qiagen) with UMI-based correction.</p>
</sec>
<sec id="s3-7">
<title>Primary cultured cortical neurons</title>
<p>Pregnant female Sprague-Dawley (SD) rats were supplied by BioLASCO Taiwan Co., Ltd. (Yilan, Taiwan). All animals (one rat/individually ventilated cage) were housed in an air-conditioned room (22 &#xb1; 2&#xb0;C) on a 12 hr-light/dark cycle (07:00&#x2013;19:00&#xa0;h light) and had free access to food and water. To prepare primary cultured cortical neurons, embryonic day 17 fetal rat brains were obtained from pregnant female SD rats of 17-day gestation which were sacrificed by an overdose of Zoletil<sup>&#xae;</sup> (Virbac, Taipei, Taiwan) to minimize pain or discomfort used. The use of animals and all experiments conducted were under approved protocols from the Institutional Animal Care and Use Committee (IACUC) of Taipei Veterans General Hospital, Taipei, Taiwan. The approval number is IACUC2022-235. In addition, the authors complied with the ARRIVE guidelines. All experiments were performed in accordance with relevant guidelines and regulations.</p>
<p>Cerebral cortices of fetal rats were isolated and dissociated mechanically. The dissociated cells were suspended in the Basal Medium Eagle medium (BME, Thermo Fisher Scientific) containing 20% fetal bovine serum, and were seeded onto a 35-mm culture dish (IWAKI, Tokyo, Japan) with a density of 5 &#xd7; 10<sup>6</sup> cells per dish. Afterwards, cells were maintained with serum-free NB medium supplemented with B27 (Thermo Fisher Scientific) in the incubator with 5% CO<sub>2</sub> at 37&#xb0;C. Hemin-induced neurotoxicity was established by exposing primary cultured cortical neurons with hemin (30&#xa0;&#x3bc;M).</p>
</sec>
<sec id="s3-8">
<title>Cytotoxicity assay</title>
<p>A modified sulforhodamine B (SRB) assay was employed to measure cell viability. At the end of experiment, cells in 96-well plates were washed with phosphate-buffered saline (PBS) and 10% trichloroacetic acid (TCA, Merck, Boston, MA, United States) and were then incubated at 4&#xb0;C for 1h. Afterwards, TCA solution was removed, and the cells were washed with double distilled H<sub>2</sub>O. Cells were then incubated with SRB solution (0.4% in 1% acetic acid, Merck) for 10&#xa0;min. Afterwards, SRB solution was removed, and the cells were washed with 1% acetic acid. After removing acetic acid, the sample was air-dried and 20&#xa0;mM unbuffered Tris base was used to dissolve the resulting formazan product. The absorption was measured by an ELISA reader (TECAN Sunrise, M&#xe4;nnedorf, United States) at 540&#xa0;nm with a reference wavelength of 690&#xa0;nm.</p>
</sec>
<sec id="s3-9">
<title>Western blots analysis</title>
<p>At the end of 16-h treatments, the cells were collected, washed with phosphate buffered saline (PBS), and lysed in radioimmunoprecipitation assay (RIPA, Cell Signaling Tech. Beverly, MA, United States) lysis buffer containing 20&#xa0;mM Tris HCl, 150&#xa0;mM NaCl, 1% (v/v) NP-40, 1% (w/v) sodium deoxycholate, 1&#xa0;mM ethylenediaminetetraacetates (EDTA), 0.1% (w/v) sodium dodecyl sulfate polyacrylamide (SDS) and 0.01% (w/v) sodium azide (pH 7.5) for 20&#xa0;min on ice. Lysates were then centrifuged at 13800 &#xd7; <italic>g</italic> for 10&#xa0;min, and the protein concentrations of supernatants were determined by Pierce BCA Protein Assay Kit (Thermo Fisher Scientific). Protein samples (30&#xa0;&#x3bc;g) were run on 12&#x2013;13.5% SDS-polyacrylamide gel electrophoresis and then transferred onto a polyvinylidene difluoride (PVDF, Bio-Rad, Hercules, CA, United States) at 100&#xa0;V for 120&#xa0;min. Blots were probed with primary antibodies including antibodies against GAP43 (Cell Signaling Technology), iNOS, COX-2, HO-1 (StressGen, Victoria, CA, United States), GPX4 and active-caspase 3 (Cell Signaling Technology) overnight at 4&#xb0;C. After incubation of primary antibodies, the membrane was washed and incubated with a secondary antibody for 1&#xa0;h at room temperature. The secondary antibodies were horseradish peroxidase-conjugated secondary IgG (Chemicon, Temecula, CA, United States). The immunoreaction was visualized using Amersham Enhanced Chemiluminescence (Amersham Pharmacia Biotech, Piscataway, NJ, United States). After this measurement, the bound primary and secondary antibodies were stripped by incubating the membrane in stripping buffer (100&#xa0;mM 2-mercaptoethanol, 2% SDS) at 50&#xb0;C for 5&#xa0;min. The membrane was reprobed with a primary antibody against &#x3b2;-actin (Millipore, Billerica, MA, United States).</p>
</sec>
<sec id="s3-10">
<title>Immunofluorescent staining</title>
<p>At the end of treatments, the primary cultured cortical neurons were fixed with 4% paraformaldehyde (Merck). Cells were then washed with 0.1&#xa0;M PBS, incubated with 0.3% Triton X-100 (Sigma) and 1% goat serum (GS; Jackson ImmunoResearch, West Grove, PA, United States), and blocked with 3% GS for 60&#xa0;min. Next, cells were processed for immunostaining using monoclonal antibody specific for rat Neu N (Cell Signaling Technology) in 1% GS-PBS at 4&#xb0;C for 24&#xa0;h. The cells were then incubated in fluorescein conjugated-IgG (FITC) (Jackson ImmunoResearch) for 1&#xa0;h at room temperature, mounted in glycerol (Merck) and exosome stained with PKH26 (Sigma). Controls consisted of omissions of primary antibodies. The sections were visualized by a fluorescence confocal microscope (Olympus FluoView, Norfolk, VA, United States).</p>
</sec>
<sec id="s3-11">
<title>Statistics</title>
<p>All data are expressed as the mean &#xb1; S.E.M. The results were analyzed by one-way analysis of variance (one-way ANOVA) followed by the LSD test (cell viability and Western blot assay) or Tukey multiple comparison (NTA) as <italic>post hoc</italic> methods. The significance level was set at p &#x3c; 0.05.</p>
</sec>
</sec>
<sec sec-type="results" id="s4">
<title>Results</title>
<sec id="s4-1">
<title>Characterization of exosomes of hypoxic preconditioned CTX-TNA2 cells</title>
<p>To delineate the effect of hypoxic preconditionings on exosome secretion, CTX-TNA2 astrocyte cells were treated with 3, 6, and 12&#xa0;h hypoxia. SRB assay showed that hypoxia (1% oxygen) for 3, 6, 12&#xa0;h did not cause significant cell loss of CTX-TNA2 cells (<xref ref-type="fig" rid="F1">Figure 1A</xref>). Therefore, 2-h hypoxia followed by 6-h normoxia (2H/6R) and 12-h hypoxia followed by 24-h normoxia (12H/24R) were designed to treat CTX-TNA2 cells to harvest exosomes (<xref ref-type="fig" rid="F1">Figure 1B</xref>). Western blot assay showed that compared with the control, Aix and CD 63 levels were elevated in the 2H/6R exosomes and 12H/24R exosomes (<xref ref-type="fig" rid="F1">Figure 1C</xref>). TEM analysis showed that control exosomes, 2H/6R exosomes and 12H/24R exosomes all exhibited a spherical morphology with an intact lipid bilayer membrane (<xref ref-type="fig" rid="F1">Figure 1D</xref>). Furthermore, the NTA assay showed that the sizes of 2H/6R exosomes and 12H/24R exosomes were slightly larger but not statistically different from the control exosomes, ranging from 89.8 &#xb1; 9.9&#xa0;nm in the control exosomes to 99.4 &#xb1; 12.7&#xa0;mm in 2H/6R exosomes and 105.1 &#xb1; 22.3&#xa0;nm in the 12H/24R exosomes (n &#x3d; 3/group) (<xref ref-type="table" rid="T1">Table 1</xref>). At the same time, the concentrations of exosomes particles were not statistically different among 3 exosomes (<xref ref-type="table" rid="T1">Table 1</xref>). Furthermore, no statistical differences were observed in zeta potentials of 3 exosomes (<xref ref-type="table" rid="T1">Table 1</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Characterization of exosomes secreted from CTX-TNA2 cells subjected to different hypoxic preconditionings. <bold>(A)</bold> CTX-TNA2 cells were treated with hypoxia for 3, 6, and 12&#xa0;h. Cell viability was measured using SRB assay. Values are the mean &#xb1; S.E.M. (n &#x3d; 3/each group). No statistical signifijcance was observed using one-way ANOVA followed by the LSD test as <italic>post hoc</italic> method. <bold>(B)</bold> The diagram illustrated two different hypoxic preconditioings of CTX-TNA2 cells for exosomes collection. One was 2H/6R exosomes which were obtained from CTX-TNA2 cells exposed to 2-h hypoxia followed by 6-h normoxia. The other was 12H/24R exosomes which were obtained from CTX-TNA2 cells exposed to 12-h hypoxia followed by 24-h normoxia <bold>(C,D)</bold> 2H/6R exosomes, 12H/24R exosomes and control exosomes obtained from 1 &#xd7; 10<sup>6</sup> CTX-TNA2 cells were used. Western blot assay was employed to measure exosomal markers, including Alix and CD63 <bold>(C)</bold>. TEM images of control exosomes, 2H/6R exosomes and 12H/24R exosomes were performed <bold>(D)</bold>. Representative exosomes were indicated by arrows in each images. Scale bar &#x3d; 200&#xa0;nm.</p>
</caption>
<graphic xlink:href="ebm-250-10559-g001.tif"/>
</fig>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>NTA assay of 2H/6R exosomes and 12H/24R exosomes. 2H/6R exosomes were obtained from CTX-TNA2 cells exposed to 2-h hypoxia followed by 6-h normoxia. The other was 12H/24R exosomes obtained from cells exposed to 12-h hypoxia followed by 24-h normoxia. NTA assay and zeta potential assay were performed. Values are the mean &#xb1; S.E.M. (n &#x3d; 3/each group). No statistical signifijcance was observed using one-way ANOVA followed by the Tukey multiple comparison as <italic>post hoc</italic> method.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="center">Exosomes&#x2019; conditions</th>
<th align="center">Size (nm)</th>
<th align="center">Concentration (particles/mL)</th>
<th align="center">Zeta potential (mV)</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="center">Control exosomes</td>
<td align="right">89.8 &#xb1; 9.9</td>
<td align="right">1.25 &#xb1; 0.35 &#xd7; 10<sup>10</sup>
</td>
<td align="right">&#x2212;8.57 &#xb1; 0.27</td>
</tr>
<tr>
<td align="center">2H/6R exosomes</td>
<td align="right">99.4 &#xb1; 9.0</td>
<td align="right">1.04 &#xb1; 0.29 &#xd7; 10<sup>10</sup>
</td>
<td align="right">&#x2212;8.72 &#xb1; 0.87</td>
</tr>
<tr>
<td align="center">12H/24R exosomes</td>
<td align="right">105.1 &#xb1; 22.3</td>
<td align="right">1.40 &#xb1; 0.64 &#xd7; 10<sup>10</sup>
</td>
<td align="right">&#x2212;7.48 &#xb1; 0.80</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s4-2">
<title>Differential effects of exosomes of hypoxic preconditioned CTX-TNA2 cells on hemin-induced cell death and morphological changes</title>
<p>To delineate the effects of 2H/6R exosomes and 12H/24R exosomes, a hemin-induced neurotoxicity model was established in primary cultured cortical neurons. The SRB assay showed that 16-h incubation of hemin (30&#xa0;&#x3bc;M) increased neuronal death (<xref ref-type="fig" rid="F2">Figure 2A</xref>). Co-incubation with 2H/6R exosomes concentration-dependently attenuated hemin-induced neuronal death. In contrast, 12H/24R exosomes did not significantly alter hemin-induced neuronal death (<xref ref-type="fig" rid="F2">Figure 2A</xref>). At the same time, Western blot assay showed that hemin reduced GAP43 levels (a biomarker of neurite outgrowth). Co-incubation of 2H/6R exosomes, but not 12H/24R exosomes, attenuated hemin-induced reduction in GAP 43 levels, indicating that 2H/6R exosomes may attenuate hemin-induced reduction of neurite outgrowth (<xref ref-type="fig" rid="F2">Figures 2B,C</xref>). Moreover, the immunofluorescent staining data showed focal bead-like swellings, neuritic beading and discontinuities of neurites in hemin-treated primary cultured cortical neurons after 1-h incubation of hemin, indicating hemin-induced impairments in neurite outgrowth (<xref ref-type="fig" rid="F3">Figure 3</xref>). Co-incubation of 2H/6R exosomes significantly attenuated hemin-induced neurite impairment (<xref ref-type="fig" rid="F3">Figure 3</xref>). At the same time, intensive PKH26 fluorescence (a fluorescent dye specific for exosomes) was detected in the cytosol of primary cultured cortical neurons treated with hemin plus 2H/6R exosomes, suggesting that exosomes were successfully endocytosed by primary cultured cortical neurons.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Differential effects of 2H/6R exosomes and 12H/24R exosomes on hemin neurotoxicity in primary cultured cortical neurons. <bold>(A)</bold> Primary cultured cortical neurons were treated with hemin (30&#xa0;&#x3bc;M) plus 2H/6R exosomes obtained from 1 &#xd7; 10<sup>6</sup> CTX-TNA2 cells (as 1-fold) and 12H/24R exosomes (1 fold, 3 folds) for 16&#xa0;h. Cell death was measured by SRB assay. <bold>(B,C)</bold> Primary cultured cortical neurons were treated with hemin (30&#xa0;&#x3bc;M) plus 2H/6R exosomes (1-fold) <bold>(B)</bold> and 12H/24R exosomes (1 fold and 3 folds) for 16&#xa0;h. Western blot assay was employed to measure GAP43. Each lane contained 30&#xa0;&#x3bc;g protein for all experiments. Graphs show statistic results from relative optical density of bands on the blots. Values are the mean &#xb1; S.E.M. (n &#x3d; 3/each group). &#x2a;, p &#x3c; 0.05 statistically significant in the hemin groups compared with the control groups; &#x23;, P &#x3c; 0.05 in hemin plus exosomes compared with hemin alone by one-way ANOVA followed by the LSD test as <italic>post hoc</italic> method.</p>
</caption>
<graphic xlink:href="ebm-250-10559-g002.tif"/>
</fig>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Differential effects of 2H/6R exosomes and 12H/24R exosomes on hemin-induced impairment of neurite outgrowth in primary cultured cortical neurons. Primary cultured cortical neurons were treated with hemin (30&#xa0;&#x3bc;M) plus 2H/6R exosomes obtained from 1 &#xd7; 10<sup>6</sup> CTX-TNA2 cells for 1&#xa0;h. The cells were immunostained with Neu N, PHK26 and DAPI. Calibration: 10&#xa0;&#x3bc;m. The results were duplicated.</p>
</caption>
<graphic xlink:href="ebm-250-10559-g003.tif"/>
</fig>
</sec>
<sec id="s4-3">
<title>Differential effects of exosomes of hypoxic preconditioned CTX-TNA2 cells on hemin-induced neuroinflammation, HO-1 expression and programmed cell death</title>
<p>To further investigate the differential effects of 2H/6R exosomes and 12H/24R exosomes, iNOS and COX-2 (two proinflammatory biomarkers) were measured in the primary cultured cortical neurons. Western blot assay demonstrated hemin (30&#xa0;&#x3bc;M)-induced neuroinflammation by increasing iNOS (<xref ref-type="fig" rid="F4">Figures 4A,B</xref>) and COX-2 (<xref ref-type="fig" rid="F4">Figures 4C,D</xref>) in hemin-treated primary cultured cortical neurons. Co-incubation with 2H/6R exosomes significantly prevented hemin-induced elevations in iNOS (<xref ref-type="fig" rid="F4">Figure 4A</xref>) and COX-2 (<xref ref-type="fig" rid="F4">Figure 4C</xref>). In contrast, 12H/24R exosomes further increased hemin-elevated iNOS (<xref ref-type="fig" rid="F4">Figure 4B</xref>) and COX-2 (<xref ref-type="fig" rid="F4">Figure 4D</xref>). These data indicated opposite effects of 2H/6R exosomes and 12H/24R exosomes on hemin-induced neuroinflammation. At the same time, we investigated the effects of exosomes on HO-1 expression (an enzyme catalyzing hemin). Western blot assay showed that co-incubation of H/6R exosomes but not 12H/24R significantly attenuated hemin-induced elevation in HO-1 expression (<xref ref-type="fig" rid="F5">Figure 5</xref>), suggesting that 2H/6R exosomes can reduce hemin-induced HO-1 expression.</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Differential effects of 2H/6R exosomes and 12H/24R exosomes on hemin-induced neuroinflammation in primary cultured cortical neurons. <bold>(A,C)</bold> Primary cultured cortical neurons were treated with hemin (30&#xa0;&#x3bc;M) plus 2H/6R exosomes obtained from 1 &#xd7; 10<sup>6</sup> CTX-TNA2 cells (as 1 fold) for 16&#xa0;h <bold>(B,D)</bold> Primary cultured cortical neurons were treated with hemin (30&#xa0;&#x3bc;M) plus 12H/24R exosomes (1 fold and 3 folds) for 16&#xa0;h. Western blot assay was employed to measure iNOS <bold>(A,B)</bold> and COX-2 <bold>(C,D)</bold>. Each lane contained 30&#xa0;&#x3bc;g protein for all experiments. Graphs show statistic results from relative optical density of bands on the blots. Values are the mean &#xb1; S.E.M. (n &#x3d; 3/each group). &#x2a;, p &#x3c; 0.05 statistically significant in the hemin groups compared with the control groups; &#x23;, P &#x3c; 0.05 in hemin plus exosomes compared with hemin alone by one-way ANOVA followed by the LSD test as <italic>post hoc</italic> method.</p>
</caption>
<graphic xlink:href="ebm-250-10559-g004.tif"/>
</fig>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>Differential effects of 2H/6R exosomes and 12H/24R exosomes on hemin-induced HO-1 expression in primary cultured cortical neurons. <bold>(A)</bold> Primary cultured cortical neurons were treated with hemin (30&#xa0;&#x3bc;M) plus 2H/6R exosomes obtained from 1 &#xd7; 10<sup>6</sup> CTX-TNA2 cells (as 1-fold) for 16&#xa0;h. <bold>(B)</bold> Primary cultured cortical neurons were treated with hemin (30&#xa0;&#x3bc;M) plus 12H/24R exosomes (1 fold and 3 folds) for 16&#xa0;h. Western blot assay was employed to measure HO-1. Each lane contained 30&#xa0;&#x3bc;g protein for all experiments. Graphs show statistic results from relative optical density of bands on the blots. Values are the mean &#xb1; S.E.M. (n &#x3d; 3/each group). &#x2a;, p &#x3c; 0.05 statistically significant in the hemin groups compared with the control groups; &#x23;, P &#x3c; 0.05 in hemin plus exosomes compared with hemin alone by one-way ANOVA followed by the LSD test as <italic>post hoc</italic> method.</p>
</caption>
<graphic xlink:href="ebm-250-10559-g005.tif"/>
</fig>
<p>The neurotoxic mechanisms underlying hemin-induced neuronal death were investigated by measuring glutathione hydroperoxidase 4 (GPX4, a biomarker of ferroptosis) and active caspase 3 (a biomarker of apoptosis). Western blot assay demonstrated that hemin (30&#xa0;&#x3bc;M) reduced GPX4 (<xref ref-type="fig" rid="F6">Figures 6A,B</xref>) and increased active caspase 3 (<xref ref-type="fig" rid="F6">Figures 6C,D</xref>). Co-incubation with 2H/6R exosomes attenuated hemin-induced reduction in GPX4 (<xref ref-type="fig" rid="F6">Figure 6A</xref>) and elevation in active caspase 3 (<xref ref-type="fig" rid="F6">Figure 6C</xref>). In contrast, 12H/24R exosomes did not alter hemin-induced reduction in GPX4 (<xref ref-type="fig" rid="F6">Figure 6B</xref>) and elevation in active caspase 3 (<xref ref-type="fig" rid="F6">Figure 6D</xref>), indicating indicate that 2H/6R exosomes appear to reduce hemin-induced ferroptosis and apoptosis.</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>Differential effects of 2H/6R exosomes and 12H/24R exosomes on hemin-induced programmed cell death in primary cultured cortical neurons. <bold>(A,C)</bold> Primary cultured cortical neurons were treated with hemin (30&#xa0;&#x3bc;M) plus 2H/6R exosomes obtained from 1 &#xd7; 10<sup>6</sup> CTX-TNA2 cells (as 1 fold) for 16&#xa0;h <bold>(B,D)</bold> Primary cultured cortical neurons were treated with hemin (30&#xa0;&#x3bc;M) plus 12H/24R exosomes (1 fold and 3 folds) for 16&#xa0;h. Western blot assay was employed to measure GPX4 <bold>(A,B)</bold> and active-caspase 3 <bold>(C,D)</bold>. Each lane contained 30&#xa0;&#x3bc;g protein for all experiments. Graphs show statistic results from relative optical density of bands on the blots. Values are the mean &#xb1; S.E.M. (n &#x3d; 3/each group). &#x2a;, p &#x3c; 0.05 statistically significant in the hemin groups compared with the control groups; &#x23;, P &#x3c; 0.05 in hemin plus exosomes compared with hemin alone by one-way ANOVA followed by the LSD test as <italic>post hoc</italic> method.</p>
</caption>
<graphic xlink:href="ebm-250-10559-g006.tif"/>
</fig>
</sec>
<sec id="s4-4">
<title>Diverse cargos in 2H/6R exosomes and 12H/24R exosomes</title>
<p>So far, we have demonstrated differential effects of 2H/6R exosomes and 12H/24R exosomes on hemin-induced neurotoxicity; 2H/6R exosomes, but not 12H/24R exosomes, possessed a neuroprotective activity. The cargos, especially miRNA in both exosomes were analyzed using RNA Sequencing Analysis. We found significant changes in the miRNA expression profiles, including the expression levels of let-7c-5p, miR-191a-5p, and miR-709 in 2H/6R exosomes (<xref ref-type="fig" rid="F7">Figure 7</xref>).</p>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption>
<p>Cargos in control exosomes, 2H/6R and 12H/24R exosomes by miRNA sequencing analysis. Sequencing was performed with single-end reads (100 bp) at a depth exceeding 10 million reads per sample. miRNA expression levels were analyzed on the Qiagen GeneGlobe platform with UMI-based correction.</p>
</caption>
<graphic xlink:href="ebm-250-10559-g007.tif"/>
</fig>
</sec>
</sec>
<sec sec-type="discussion" id="s5">
<title>Discussion</title>
<p>In the present study, the effects of hypoxia on exosomes obtained from CTX-TNA2 cells exposed to different hypoxic preconditionings were delineated using hemin-induced neurotoxicity as follows. First, compared to the control exosomes, 2H/6R exosomes and 12H/24R exosomes did not show significant difference in exosomes secretion. Secondly, 2H/6R exosomes showed neuroprotective properties by attenuating hemin-induced neurotoxicity. However, 12H/24R exosomes appear to be proinflammatory by augmenting hemin-induced neuroinflammation. Our study showed that exosomes from CTX-TNA2 cells subjected to different hypoxic preconditionings possess opposite properties, suggesting that hypoxia plays a double-edged role in exosome&#x2019;s functions.</p>
<p>Hypoxia, a condition of insufficient oxygen, is reportedly an external factor that stimulates exosome secretion [<xref ref-type="bibr" rid="B22">22</xref>, <xref ref-type="bibr" rid="B23">23</xref>]. Several <italic>in vitro</italic> studies on cancer biology have demonstrated that incubation of cancer cells under hypoxia (1% oxygen for 24&#x2013;72&#xa0;h) which mimicked hypoxia in the tumor microenvironment, increased exosome releases [<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B23">23</xref>]. At the same time, exosomes from hypoxic cancer cells contain proangiogenic miRNA and growth factors for angiogenesis and cancer cell proliferation, respectively [<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B24">24</xref>], indicating that in addition to exosome secretion, hypoxia is capable of altering exosome&#x2019;s properties [<xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B24">24</xref>]. To support this notion, two different hypoxic preconditionings were designed to treat CTX-TNA2 cells and collect exosomes from the cultured medium individually. Our data showed that hypoxia preconditionings significantly increased exosome biomarkers and slight increases in exosome size. Due to the lack of differences in particle concentration, one possible explanation is that more exosome biomarkers are expressed in each exosome. Our data suggested that hypoxic preconditioning did not significantly affect exosome secretion.</p>
<p>In contrast, hypoxic preconditioning significantly changed the properties of exosomes. To delineate the exosome&#x2019;s properties, we employed hemin [<xref ref-type="bibr" rid="B18">18</xref>] which is commonly used to mimic ICH-related secondary injury [<xref ref-type="bibr" rid="B25">25</xref>], including cytotoxicity, neurite impairment, HO-1 expression, neuroinflammation and program cell death. Hemin, a byproduct of hemoglobin degradation [<xref ref-type="bibr" rid="B26">26</xref>], is known as an HO-1 inducer to catalyze the degradation of heme/hemin and release iron [<xref ref-type="bibr" rid="B27">27</xref>], a Fenton&#x2019;s reagent which induce oxidative injury and subsequent cell death [<xref ref-type="bibr" rid="B28">28</xref>]. We found that 2H/6R exosomes attenuated hemin-induced neuronal death, neurite impairment and neuroinflammation. More importantly, 2H/6R exosomes significantly inhibited hemin-elevated HO-1 levels which resulted in less iron accumulation and ameliorated subsequent apoptosis and ferroptosis, a programmed cell death related to iron metabolism. In contrast to the 2H/6R exosomes-induced neuroprotection, 12H/24R exosomes significantly augmented hemin-induced elevation in iNOS and COX-2, indicating that 12H/24R exosomes is proinflammatory. Due to the opposite effects of 2H/6R exosomes and 12H/24R exosomes on hemin-induced neurotoxicity, our data further support that hypoxia plays a double-edged role in regulating exosome functions.</p>
<p>A significant body of studies has focused on the pathological effects of hypoxia on CNS, including ICH. The pathophysiology of hypoxia depends on the duration of hypoxia, including acute, subacute and chronic hypoxia [<xref ref-type="bibr" rid="B29">29</xref>]. In addition to 2H/6R and 12H/24R, more hypoxia-renormoxia treatments were tested, including 3H/24R, 6H/24R, and 12H/24R (unpublished data). To avoid obtaining exosomes from unhealthy cells, we chose hypoxic duration from 2 to 12&#xa0;h because hypoxia duration less than 12&#xa0;h did not cause significant cytotoxicity. All cells are capable of releasing exosomes [<xref ref-type="bibr" rid="B1">1</xref>&#x2013;<xref ref-type="bibr" rid="B3">3</xref>], including brain cells. In addition to CTX-TNA2 cells, we have tested different hypoxia-renormoxia conditions on primary cultured cortical neurons. The exosomes from primary cultured cortical neurons showed different biological activities from those from CTX-TNA2 (unpublished data). Accordingly, types and conditions of donor cells are the critical factors for exosome production [<xref ref-type="bibr" rid="B30">30</xref>].</p>
<p>To obtain &#x201c;good&#x201d; exosomes from hypoxic cells, it is important to design an ideal hypoxic condition, including optimal duration (2&#x2013;72&#xa0;h) [<xref ref-type="bibr" rid="B14">14</xref>] and intensity (0.1%&#x2013;5% oxygen) [<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B31">31</xref>]. For example, exosomes obtained from MSCs subjected to 48-h hypoxia (1% O2) were reportedly more efficacious to bone fracture healing [<xref ref-type="bibr" rid="B10">10</xref>]. In addition, exosomes from hypoxic donor cells (3% for 24&#xa0;h) were found to be neuroprotective to attenuate program cell death induced by OGD/reperfusion [<xref ref-type="bibr" rid="B32">32</xref>]. &#x201c;As an important intercellular mediator, &#x201c;cargos&#x201d; in the exosomes, including miRNAs, are the key element for its functions [<xref ref-type="bibr" rid="B30">30</xref>]. For example, miR-92b-3p in the exosomes released from OGD-treated astrocytes has been suggested to mediate the neuroprotection against OGD-induced neurotoxicity [<xref ref-type="bibr" rid="B33">33</xref>]. Furthermore, exosome-delivered miR216a-5p from hypoxic preconditioned-MSCs is suggested to repair spinal cord injury [<xref ref-type="bibr" rid="B34">34</xref>]. In the present study, we identified several miRNAs elevated in the 2H/6R exosomes, including let-7c-5p which has been suggested to be neuroprotective against cerebral ischemia [<xref ref-type="bibr" rid="B35">35</xref>]. Accordingly, 2H/6R treatment may produce &#x201c;good&#x201d; exosomes for neuroprotection.</p>
<p>In conclusion, hypoxia has been used as a strategy to enhance exosome secretion. However, beyond the quantity of released exosomes, it is equally important to characterize how hypoxia simultaneously affects exosomes&#x2019; properties. Given that function of exosomes is closely tied to the conditions of donor cells, our data demonstrated that CTX-TNA2 cells exposed to varying hypoxia-renormoxia treatments produce exosomes with opposite functional profiles. The present study demonstrates the complex effects of hypoxia as well as a double-edged role of hypoxia on exosome functionality.</p>
</sec>
</body>
<back>
<sec sec-type="author-contributions" id="s6">
<title>Author contributions</title>
<p>All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.</p>
</sec>
<sec id="s7">
<title>Data availability</title>
<p>The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.</p>
</sec>
<sec sec-type="ethics-statement" id="s8">
<title>Ethics statement</title>
<p>The animal study was approved by the Institutional Animal Care and Use Committee (IACUC) of Taipei Veterans General Hospital (TVGH), Taipei, Taiwan. The study was conducted in accordance with the local legislation and institutional requirements.</p>
</sec>
<sec sec-type="funding-information" id="s9">
<title>Funding</title>
<p>The author(s) declare that financial support was received for the research and/or publication of this article. The NSTC grant NSTC 113-2320-B-A49-033 and VGHTPE grant V113C-022.</p>
</sec>
<sec sec-type="COI-statement" id="s10">
<title>Conflict of interest</title>
<p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</sec>
<sec sec-type="ai-statement" id="s11">
<title>Generative AI statement</title>
<p>The authors declare that no Generative AI was used in the creation of this manuscript.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>WH</given-names>
</name>
</person-group>. <article-title>Exosomes: biogenesis, biologic function and clinical potential</article-title>. <source>Cell Biosci</source> (<year>2019</year>) <volume>9</volume>:<fpage>19</fpage>. <pub-id pub-id-type="doi">10.1186/s13578-019-0282-2</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>St&#xe5;hl</surname>
<given-names>Al</given-names>
</name>
<name>
<surname>Johansson</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Mossberg</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kahn</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Karpman</surname>
<given-names>D</given-names>
</name>
</person-group>. <article-title>Exosomes and microvesicles in normal physiology, pathophysiology, and renal diseases</article-title>. <source>Pediatr Nephrol</source> (<year>2019</year>) <volume>34</volume>:<fpage>11</fpage>&#x2013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1007/s00467-017-3816-z</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krylova</surname>
<given-names>SV</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>D</given-names>
</name>
</person-group>. <article-title>The machinery of exosomes: biogenesis, release, and uptake</article-title>. <source>Int J Mol Sci</source> (<year>2023</year>) <volume>24</volume>:<fpage>1337</fpage>. <pub-id pub-id-type="doi">10.3390/ijms24021337</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group> <article-title>Hypoxia induced changes of exosome cargo and subsequent biological effects</article-title>. <source>Front Immunol</source> (<year>2022</year>) <volume>13</volume>:<fpage>824188</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2022.824188</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rahmati</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Shojaei</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Shojaeian</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rezakhani</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Dehkordi</surname>
<given-names>MB</given-names>
</name>
</person-group>. <article-title>An overview of current knowledge in biological functions and potential theragnostic applications of exosomes</article-title>. <source>Chem Phys Lipids</source> (<year>2020</year>) <volume>226</volume>:<fpage>104836</fpage>. <pub-id pub-id-type="doi">10.1016/j.chemphyslip.2019.104836</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lotfy</surname>
<given-names>A</given-names>
</name>
<name>
<surname>AboQuella</surname>
<given-names>NM</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Mesenchymal stromal/stem cell (MSC)-derived exosomes in clinical trials</article-title>. <source>Stem Cel Res Ther</source> (<year>2023</year>) <volume>14</volume>:<fpage>66</fpage>. <pub-id pub-id-type="doi">10.1186/s13287-023-03287-7</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>R&#xf8;sand</surname>
<given-names>&#xd8;</given-names>
</name>
<name>
<surname>H&#xf8;ydal</surname>
<given-names>MA</given-names>
</name>
</person-group>. <article-title>Cardiac exosomes in ischemic heart disease- A narrative review</article-title>. <source>Diagnostics (Basel)</source> (<year>2021</year>) <volume>11</volume>:<fpage>269</fpage>. <pub-id pub-id-type="doi">10.3390/diagnostics11020269</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shokravi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Borisov</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Zaman</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Niazvand</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Hazrati</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Khah</surname>
<given-names>MM</given-names>
</name>
<etal/>
</person-group> <article-title>Mesenchymal stromal cells (MSCs) and their exosome in acute liver failure (ALF): a comprehensive review</article-title>. <source>Stem Cel Res Ther</source> (<year>2022</year>) <volume>13</volume>:<fpage>192</fpage>. <pub-id pub-id-type="doi">10.1186/s13287-022-02825-z</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamashita</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Takakura</surname>
<given-names>Y</given-names>
</name>
</person-group>. <article-title>Possibility of exosome-based therapeutics and challenges in production of exosomes eligible for therapeutic application</article-title>. <source>Biol Pharm Bull</source> (<year>2018</year>) <volume>41</volume>:<fpage>835</fpage>&#x2013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1248/bpb.b18-00133</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Rong</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Qian</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Z</given-names>
</name>
<etal/>
</person-group> <article-title>Hypoxic mesenchymal stem cell-derived exosomes promote bone fracture healing by the transfer of miR-126</article-title>. <source>Acta Biomater</source> (<year>2020</year>) <volume>103</volume>:<fpage>196</fpage>&#x2013;<lpage>212</lpage>. <pub-id pub-id-type="doi">10.1016/j.actbio.2019.12.020</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Michiels</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>Physiological and pathological responses to hypoxia</article-title>. <source>Am J Pathol</source> (<year>2004</year>) <volume>164</volume>:<fpage>1875</fpage>&#x2013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1016/s0002-9440(10)63747-9</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Chandel</surname>
<given-names>NS</given-names>
</name>
<name>
<surname>Simon</surname>
<given-names>MC</given-names>
</name>
</person-group>. <article-title>Cellular adaptation to hypoxia through hypoxia inducible factors and beyond</article-title>. <source>Nat Rev Mol Cel Biol</source> (<year>2020</year>) <volume>21</volume>:<fpage>268</fpage>&#x2013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1038/s41580-020-0227-y</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>King</surname>
<given-names>HW</given-names>
</name>
<name>
<surname>Michael</surname>
<given-names>MZ</given-names>
</name>
<name>
<surname>Gleadle</surname>
<given-names>JM</given-names>
</name>
</person-group>. <article-title>Hypoxic enhancement of exosome release by breast cancer cells</article-title>. <source>BMC Cancer</source> (<year>2012</year>) <volume>12</volume>:<fpage>421</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2407-12-421</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeng</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Niu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>Z</given-names>
</name>
<etal/>
</person-group> <article-title>Hypoxic exosomal HIF-1&#x3b1;-stabilizing circZNF91 promotes chemoresistance of normoxic pancreatic cancer cells via enhancing glycolysis</article-title>. <source>Oncogene</source> (<year>2021</year>) <volume>40</volume>:<fpage>5505</fpage>&#x2013;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1038/s41388-021-01960-w</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>AM</given-names>
</name>
</person-group>. <article-title>Kainic acid-induced oxidative injury is attenuated by hypoxic preconditioning</article-title>. <source>Ann N Y Acad Sci</source> (<year>2005</year>) <volume>1042</volume>:<fpage>314</fpage>&#x2013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1196/annals.1338.054</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Dung</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>CF</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>L</given-names>
</name>
</person-group>. <article-title>Hypoxic preconditioning prevents cortical infarction by transient focal ischemia-reperfusion</article-title>. <source>Ann N Y Acad Sci</source> (<year>2003</year>) <volume>993</volume>:<fpage>168</fpage>&#x2013;<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1111/j.1749-6632.2003.tb07527.x</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tzeng</surname>
<given-names>YW</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>LY</given-names>
</name>
<name>
<surname>Chao</surname>
<given-names>PL</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Role of autophagy in protection afforded by hypoxic preconditioning against MPP&#x2b;-induced neurotoxicity in SH-SY5Y cells</article-title>. <source>Free Radic Biol Med</source> (<year>2010</year>) <volume>49</volume>:<fpage>839</fpage>&#x2013;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2010.06.004</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Syed</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Nirwane</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>Y</given-names>
</name>
</person-group>. <article-title>
<italic>In vitro</italic> models of intracerebral hemorrhage</article-title>. <source>Brain Hemorrhages</source> (<year>2022</year>) <volume>3</volume>:<fpage>105</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.hest.2022.06.002</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sofroniew</surname>
<given-names>MV</given-names>
</name>
<name>
<surname>Vinters</surname>
<given-names>HV</given-names>
</name>
</person-group>. <article-title>Astrocytes: biology and pathology</article-title>. <source>Acta Neuropathol</source> (<year>2010</year>) <volume>119</volume>:<fpage>7</fpage>&#x2013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1007/s00401-009-0619-8</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fan</surname>
<given-names>YY</given-names>
</name>
<name>
<surname>Huo</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>A1/A2 astrocytes in central nervous system injuries and diseases: angels or devils?</article-title> <source>Neurochem Int</source> (<year>2021</year>) <volume>148</volume>:<fpage>105080</fpage>. <pub-id pub-id-type="doi">10.1016/j.neuint.2021.105080</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Verkhratsky</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Butt</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Illes</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Zorec</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Semyanov</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group> <article-title>Astrocytes in human central nervous system diseases: a frontier for new therapies</article-title>. <source>Signal Transduction Targeted Ther</source> (<year>2023</year>) <volume>8</volume>:<fpage>396</fpage>. <pub-id pub-id-type="doi">10.1038/s41392-023-01628-9</pub-id>
</citation>
</ref>
<ref id="B22">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Debbi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Safina</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Levenberg</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Boosting extracellular vesicle secretion</article-title>. <source>Biotechnol Adv</source> (<year>2022</year>) <volume>59</volume>:<fpage>107983</fpage>. <pub-id pub-id-type="doi">10.1016/j.biotechadv.2022.107983</pub-id>
</citation>
</ref>
<ref id="B23">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tse</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>CF</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Gnanasekaran</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Low</surname>
<given-names>JK</given-names>
</name>
<etal/>
</person-group> <article-title>Microenvironmental hypoxia induces dynamic changes in lung cancer synthesis and secretion of extracellular vesicles</article-title>. <source>Cancers (Basel)</source> (<year>2020</year>) <volume>12</volume>:<fpage>2917</fpage>. <pub-id pub-id-type="doi">10.3390/cancers12102917</pub-id>
</citation>
</ref>
<ref id="B24">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shao</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Miao</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Shu</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group> <article-title>Role of hypoxia-induced exosomes in tumor biology</article-title>. <source>Mol Cancer</source> (<year>2018</year>) <volume>17</volume>:<fpage>120</fpage>. <pub-id pub-id-type="doi">10.1186/s12943-018-0869-y</pub-id>
</citation>
</ref>
<ref id="B25">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shao</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Tu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Pathophysiological mechanisms and potential therapeutic targets in intracerebral hemorrhage</article-title>. <source>Front Pharmacol</source> (<year>2019</year>) <volume>10</volume>:<fpage>1079</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2019.01079</pub-id>
</citation>
</ref>
<ref id="B26">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ponka</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Cell biology of heme</article-title>. <source>Am J Med Sci</source> (<year>1999</year>) <volume>318</volume>:<fpage>241</fpage>&#x2013;<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1097/00000441-199910000-00004</pub-id>
</citation>
</ref>
<ref id="B27">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Le</surname>
<given-names>LL</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>XY</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>N</given-names>
</name>
<etal/>
</person-group> <article-title>Heme oxygenase-1 mediated memorial and revivable protective effect of ischemic preconditioning on brain injury</article-title>. <source>CNS Neurosci Ther</source> (<year>2013</year>) <volume>19</volume>:<fpage>963</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1111/cns.12152</pub-id>
</citation>
</ref>
<ref id="B28">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Winterbourn</surname>
<given-names>CC</given-names>
</name>
</person-group>. <article-title>Toxicity of iron and hydrogen peroxide: the Fenton reaction</article-title>. <source>Toxicol Lett</source> (<year>1995</year>) <volume>82-83</volume>:<fpage>969</fpage>&#x2013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1016/0378-4274(95)03532-x</pub-id>
</citation>
</ref>
<ref id="B29">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mukandala</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Tynan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Lanigan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>O&#x2019;Connor</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>The effects of hypoxia and inflammation on synaptic signaling in the CNS</article-title>. <source>Brain Sci</source> (<year>2016</year>) <volume>6</volume>:<fpage>6</fpage>. <pub-id pub-id-type="doi">10.3390/brainsci6010006</pub-id>
</citation>
</ref>
<ref id="B30">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Qu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X</given-names>
</name>
<etal/>
</person-group> <article-title>Role of hypoxic exosomes and the mechanisms of exosome release in the CNS under hypoxic conditions</article-title>. <source>Front Neurol</source> (<year>2023</year>) <volume>14</volume>:<fpage>1198546</fpage>. <pub-id pub-id-type="doi">10.3389/fneur.2023.1198546</pub-id>
</citation>
</ref>
<ref id="B31">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bai</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Pei</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>Y</given-names>
</name>
</person-group>. <article-title>Exosomes from hypoxia-treated human adipose-derived mesenchymal stem cells enhance angiogenesis through VEGF/VEGF-R</article-title>. <source>Int J Biochem and Cel Biol</source> (<year>2019</year>) <volume>109</volume>:<fpage>59</fpage>&#x2013;<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1016/j.biocel.2019.01.017</pub-id>
</citation>
</ref>
<ref id="B32">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deng</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Min</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>Z</given-names>
</name>
<etal/>
</person-group> <article-title>Hypoxic mesenchymal stem cell-derived exosomes promote the survival of skin flaps after ischaemia-reperfusion injury via mTOR/ULK1/FUNDC1 pathways</article-title>. <source>J Nanobiotechnology</source> (<year>2023</year>) <volume>21</volume>:<fpage>340</fpage>. <pub-id pub-id-type="doi">10.1186/s12951-023-02098-5</pub-id>
</citation>
</ref>
<ref id="B33">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X</given-names>
</name>
<etal/>
</person-group> <article-title>Exosome-shuttled miR-92b-3p from ischemic preconditioned astrocytes protects neurons against oxygen and glucose deprivation</article-title>. <source>Brain Res</source> (<year>2019</year>) <volume>1717</volume>:<fpage>66</fpage>&#x2013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainres.2019.04.009</pub-id>
</citation>
</ref>
<ref id="B34">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Rong</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Ge</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group> <article-title>Exosome-shuttled miR-216a-5p from hypoxic preconditioned mesenchymal stem cells repair traumatic spinal cord injury by shifting microglial M1/M2 polarization</article-title>. <source>J Neuroinflammation</source> (<year>2020</year>) <volume>17</volume>:<fpage>47</fpage>. <pub-id pub-id-type="doi">10.1186/s12974-020-1726-7</pub-id>
</citation>
</ref>
<ref id="B35">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ni</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X</given-names>
</name>
<etal/>
</person-group> <article-title>MicroRNA let-7c-5p protects against cerebral ischemia injury via mechanisms involving the inhibition of microglia activation</article-title>. <source>Brain Behav Immun</source> (<year>2015</year>) <volume>49</volume>:<fpage>75</fpage>&#x2013;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2015.04.014</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>